LUNDBECK REPORTS CIPRALEX STUDY RESULTS

H. Lundbeck has announced that two Phase III studies of its Cipralex antidepressant show that the drug is effective and well-tolerated in treatment of patients suffering from obsessive-compulsive disorder.

Cipralex is currently approved for the treatment of depression, panic disorder, social anxiety disorder, and generalized anxiety disorder.